FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386530734> ?p ?o ?g. }

• W4386530734 endingPage "e232951" @default.
• W4386530734 startingPage "e232951" @default.
• W4386530734 abstract "Importance Age-related macular degeneration (ARMD) therapies aflibercept and ranibizumab are among the highest-cost Medicare Part B drugs, even though off-label use of lower-cost bevacizumab is clinically noninferior. Payments from manufacturers of these ARMD therapies to ophthalmologists are hypothesized to be factors in ophthalmologists' therapeutic choice, controlling for ophthalmologist and patient characteristics. Objective To assess the association between manufacturer payments to ophthalmologists and choice of ARMD treatment as well as to identify ophthalmologist-level characteristics associated with prescribing lower-cost ARMD therapies. Design, Setting, and Participants This retrospective cross-sectional study of longitudinal (2013-2019) Medicare Part B data was conducted from December 2021 to December 2022. Ophthalmologists prescribing aflibercept (manufactured by Regeneron Pharmaceuticals Inc), rabinizumab, or bevacizumab (both manufactured by Genentech Inc) for ARMD treatment of Medicare Part B beneficiaries were included. Data on manufacturer payments to ophthalmologists were obtained from the Open Payments database. Main Outcomes and Measures The primary outcome was the percentage of bevacizumab prescribed by ophthalmologists among all ARMD therapies. Regression analysis assessed variation in bevacizumab prescribing by acceptance of manufacturer payments as well as by ophthalmologist and patient characteristics. Ophthalmologist characteristics were duration of practice and Medicare Administrative Contractor region, and patient characteristics were aggregated at the ophthalmologist level and included mean beneficiary age, percentage of dual-eligible beneficiaries, mean beneficiary risk score, and percentage of White beneficiaries. Savings were estimated by projecting the change in bevacizumab use had ophthalmologists not accepted manufacturer payments, controlling for all ophthalmologist and patient characteristics and comparing with observed use and costs. Results A total of 21 584 ophthalmologists (18 489 males [85.7%]) were included. Ophthalmologists who accepted manufacturer payments were significantly less likely to prescribe bevacizumab (28.0% [95% CI, 24.6%-42.5%] of patients) compared with those who did not accept manufacturer payments (45.8% [95% CI, 44.5%-47.1%]). Ophthalmologists who saw dual-eligible beneficiaries had greater bevacizumab prescribing (50.0% [95% CI, 40.6%-68.3%] in the highest quartile vs 36.1% [95% CI, 33.5%-38.8%] in the lowest quartile; β coefficient, 0.139; P &amp;lt; .001), while those who saw patients with higher mean beneficiary risk scores had lower bevacizumab use (38.0% [95% CI, 23.7%-44.1%] in the highest quartile vs 48.2% [95% CI, 45.5%-50.8%] in the lowest quartile; β coefficient, −0.102, P &amp;lt; .001). Had ophthalmologists who accepted manufacturer payments prescribed ARMD drugs as those who did not accept payments, Medicare spending on these treatments would have been $642 779 703.08 lower from 2013 to 2019, a 2.0% savings. Conclusions and Relevance Results of this cross-sectional study suggest that drug manufacturer payments to ophthalmologists were associated with selection of higher-cost therapies for ARMD, which is a factor in increased Medicare and patient spending. Development of manufacturer payment models that encourage ophthalmologists to choose lower-cost therapies are needed." @default.
• W4386530734 created "2023-09-09" @default.
• W4386530734 creator A5025969391 @default.
• W4386530734 creator A5053255658 @default.
• W4386530734 date "2023-09-08" @default.
• W4386530734 modified "2023-09-28" @default.
• W4386530734 title "Medicare Part B Spending on Macular Degeneration Treatments Associated With Manufacturer Payments to Ophthalmologists" @default.
• W4386530734 cites W1481978003 @default.
• W4386530734 cites W1539571840 @default.
• W4386530734 cites W1916772698 @default.
• W4386530734 cites W1975926216 @default.
• W4386530734 cites W2012407775 @default.
• W4386530734 cites W2015457963 @default.
• W4386530734 cites W2038006647 @default.
• W4386530734 cites W2042978638 @default.
• W4386530734 cites W2466725841 @default.
• W4386530734 cites W2527826246 @default.
• W4386530734 cites W2765333223 @default.
• W4386530734 cites W2795797798 @default.
• W4386530734 cites W2796852226 @default.
• W4386530734 cites W2946468044 @default.
• W4386530734 cites W2976112560 @default.
• W4386530734 doi "https://doi.org/10.1001/jamahealthforum.2023.2951" @default.
• W4386530734 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37682553" @default.
• W4386530734 hasPublicationYear "2023" @default.
• W4386530734 type Work @default.
• W4386530734 citedByCount "0" @default.
• W4386530734 crossrefType "journal-article" @default.
• W4386530734 hasAuthorship W4386530734A5025969391 @default.
• W4386530734 hasAuthorship W4386530734A5053255658 @default.
• W4386530734 hasBestOaLocation W43865307341 @default.
• W4386530734 hasConcept C10138342 @default.
• W4386530734 hasConcept C118487528 @default.
• W4386530734 hasConcept C119767625 @default.
• W4386530734 hasConcept C126322002 @default.
• W4386530734 hasConcept C145097563 @default.
• W4386530734 hasConcept C162324750 @default.
• W4386530734 hasConcept C194828623 @default.
• W4386530734 hasConcept C26869875 @default.
• W4386530734 hasConcept C2776403814 @default.
• W4386530734 hasConcept C2776694085 @default.
• W4386530734 hasConcept C2777802072 @default.
• W4386530734 hasConcept C2778749236 @default.
• W4386530734 hasConcept C2781100027 @default.
• W4386530734 hasConcept C2910449239 @default.
• W4386530734 hasConcept C512399662 @default.
• W4386530734 hasConcept C71924100 @default.
• W4386530734 hasConceptScore W4386530734C10138342 @default.
• W4386530734 hasConceptScore W4386530734C118487528 @default.
• W4386530734 hasConceptScore W4386530734C119767625 @default.
• W4386530734 hasConceptScore W4386530734C126322002 @default.
• W4386530734 hasConceptScore W4386530734C145097563 @default.
• W4386530734 hasConceptScore W4386530734C162324750 @default.
• W4386530734 hasConceptScore W4386530734C194828623 @default.
• W4386530734 hasConceptScore W4386530734C26869875 @default.
• W4386530734 hasConceptScore W4386530734C2776403814 @default.
• W4386530734 hasConceptScore W4386530734C2776694085 @default.
• W4386530734 hasConceptScore W4386530734C2777802072 @default.
• W4386530734 hasConceptScore W4386530734C2778749236 @default.
• W4386530734 hasConceptScore W4386530734C2781100027 @default.
• W4386530734 hasConceptScore W4386530734C2910449239 @default.
• W4386530734 hasConceptScore W4386530734C512399662 @default.
• W4386530734 hasConceptScore W4386530734C71924100 @default.
• W4386530734 hasIssue "9" @default.
• W4386530734 hasLocation W43865307341 @default.
• W4386530734 hasLocation W43865307342 @default.
• W4386530734 hasOpenAccess W4386530734 @default.
• W4386530734 hasPrimaryLocation W43865307341 @default.
• W4386530734 hasRelatedWork W2049577742 @default.
• W4386530734 hasRelatedWork W2123096760 @default.
• W4386530734 hasRelatedWork W2258895757 @default.
• W4386530734 hasRelatedWork W2463477672 @default.
• W4386530734 hasRelatedWork W2553987180 @default.
• W4386530734 hasRelatedWork W2577193304 @default.
• W4386530734 hasRelatedWork W2885663288 @default.
• W4386530734 hasRelatedWork W3093370884 @default.
• W4386530734 hasRelatedWork W4243304339 @default.
• W4386530734 hasRelatedWork W2085743381 @default.
• W4386530734 hasVolume "4" @default.
• W4386530734 isParatext "false" @default.
• W4386530734 isRetracted "false" @default.
• W4386530734 workType "article" @default.